https://www.selleckchem.com/products/ad-5584.html
6%) during a 5year follow-up. A quarter of patients with hypertensive LV hypertrophy and HFpEF progresses to systolic dysfunction during a 5year follow-up, which was accompanied by poor clinical outcomes. And beta-blocker therapy might play a protective role for preserved LVEF in this population. A quarter of patients with hypertensive LV hypertrophy and HFpEF progresses to systolic dysfunction during a 5 year follow-up, which was accompanied by poor clinical outcomes. And beta-blocker therapy might play a protective role for preserved
Gefällt mir
Kommentar
Teilen
